Literature DB >> 16336040

Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds.

Roland R Griffiths1, Matthew W Johnson.   

Abstract

Hypnotic drugs, including benzodiazepine receptor ligands, barbiturates, antihistamines, and melatonin receptor ligands, are useful in treating insomnia, but clinicians should consider the relative abuse liability of these drugs when prescribing them. Two types of problematic hypnotic self-administration are distinguished. First, recreational abuse occurs when medications are used purposefully for the subjective "high." This type of abuse usually occurs in polydrug abusers, who are most often young and male. Second, chronic quasi-therapeutic abuse is a problematic use of hypnotic drugs in which patients continue long-term use despite medical recommendations to the contrary. Relative abuse liability is defined as an interaction between the relative reinforcing effects (i.e., the capacity to maintain drug self-administration behavior, thereby increasing the likelihood of nonmedical problematic use) and the relative toxicity (i.e., adverse effects having the capacity to harm the individual and/or society). An algorithm is provided that differentiates relative likelihood of abuse and relative toxicity of 19 hypnotic compounds: pentobarbital, methaqualone, diazepam, flunitrazepam, lorazepam, GHB (gamma-hydroxybutyrate, also known as sodium oxybate), temazepam, zaleplon, eszopiclone, triazolam, zopiclone, flurazepam, zolpidem, oxazepam, estazolam, diphenhydramine, quazepam, tra-zodone, and ramelteon. Factors in the analysis include preclinical and clinical assessment of reinforcing effects, preclinical and clinical assessment of withdrawal, actual abuse, acute sedation/memory impairment, and overdose lethality. The analysis shows that both the likelihood of abuse and the toxicity vary from high to none across these compounds. The primary clinical implication of the range of differences in abuse liability is that concern about recreational abuse, inappropriate long-term use, or adverse effects should not deter physicians from prescribing hypnotics when clinically indicated.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336040

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  55 in total

1.  Ramelteon: a novel hypnotic indicated for the treatment of insomnia.

Authors:  Gary K Zammit
Journal:  Psychiatry (Edgmont)       Date:  2007-09

2.  Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Authors:  Timothy A Roehrs; S Randall; E Harris; R Maan; T Roth
Journal:  J Psychopharmacol       Date:  2011-10-16       Impact factor: 4.153

3.  Evaluation and treatment of poor sleep.

Authors:  Lawrence T Park; John D Matthews; Guy Maytal; Theodore A Stern
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2007

4.  Optimizing the Pharmacologic Treatment of Insomnia: Current Status and Future Horizons.

Authors:  Jared Minkel; Andrew D Krystal
Journal:  Sleep Med Clin       Date:  2013-09-01

Review 5.  Safety overview of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, dependence, and diversion.

Authors:  Y Grace Wang; Todd J Swick; Lawrence P Carter; Michael J Thorpy; Neal L Benowitz
Journal:  J Clin Sleep Med       Date:  2009-08-15       Impact factor: 4.062

6.  Therapies for insomnia and comorbid chronic obstructive pulmonary disease with a focus on ramelteon (rozerem).

Authors:  Jack Greenberg; J B Goss
Journal:  P T       Date:  2009-09

7.  Neural basis of benzodiazepine reward: requirement for α2 containing GABAA receptors in the nucleus accumbens.

Authors:  Elif Engin; Konstantin I Bakhurin; Kiersten S Smith; Rochelle M Hines; Lauren M Reynolds; Wannan Tang; Rolf Sprengel; Stephen J Moss; Uwe Rudolph
Journal:  Neuropsychopharmacology       Date:  2014-02-19       Impact factor: 7.853

8.  Hyperarousal in insomnia and hypnotic dose escalation.

Authors:  T A Roehrs; T Roth
Journal:  Sleep Med       Date:  2016-07-06       Impact factor: 3.492

9.  Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia.

Authors:  Geert Mayer; Sherry Wang-Weigand; Barbara Roth-Schechter; Reiner Lehmann; Corinne Staner; Markku Partinen
Journal:  Sleep       Date:  2009-03       Impact factor: 5.849

10.  Comparative abuse liability of GHB and ethanol in humans.

Authors:  Matthew W Johnson; Roland R Griffiths
Journal:  Exp Clin Psychopharmacol       Date:  2013-02-18       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.